Segmental Limb Volume Change as a Predictor of the Onset of Lymphedema in Women With Early Breast Cancer by Stout, Nicole L. et al.
S
M
v
c
w
i
b
c
B
p
w
M
o
R
s
C
cOriginal Research
Segmental Limb Volume Change as a Predictor of
the Onset of Lymphedema in Women With Early
Breast Cancer
Nicole L. Stout, PT, MPT, CLT-LANA, Lucinda A. Pfalzer, PT, MA, PhD, FACSM, FAPTA,
Ellen Levy, PT, OCS, Charles McGarvey, PT, DPT, MS, FAPTA,
Barbara Springer, PT, PhD, OCS, SCS, Lynn H. Gerber, MD, Peter Soballe, MDObjective: To demonstrate that segmental changes along the upper extremity occur
before the onset of breast cancer–related lymphedema (BCRL). These changes may be
subclinical in nature and may be predictive of the onset of chronic lymphedema.
Design: A retrospective subset analysis of a larger prospective cohort trial.
Patient Cohort: A total of 196 patients provided consent and were enrolled in the
prospective study. Subclinical lymphedema developed in 46 of these patients. Limb volume
data were available for 45 of these 46 patients from visits before the onset of lymphedema
and were used in this analysis. We compared this group with an age-matched control group
without BCRL from the same cohort (n  45).
etting: Military hospital outpatient breast care center.
ethods: Women were enrolled and assessed preoperatively. Baseline measures of limb
olume were obtained with the use of optoelectronic perometry, and reassessment was
onducted at 1, 3, 6, 9, and 12 months postoperatively. BCRL was identified in 46 of 196
omen at an average of 6.9 months postoperatively. A retrospective analysis was conducted
n which we examined volume changes over four 10-cm segments of the limb at the visits
efore the onset of BCRL. By using repeated-measures multivariate analysis of variance, we
ompared segmental volumes between groups at preoperative baseline, time of diagnosis of
CRL, and time of follow-up after early intervention. Linear regression analysis was
erformed to determine the strength of the relationship between total limb volume change
ith segmental volumes at the time of diagnosis of BCRL.
ain Outcome Measurements: We hypothesized that segmental volume changes
ccur and can be measured in the limb before the onset of lymphedema.
esults: At arm segments 10-20 cm (P .044) and 20-30 cm (P.001), a significant volume
increase was noted before the diagnosis of subclinical BCRL. Segmental volume changes
correlated to the total limb volume (TLV) change. At segments 20-30 cm, the coefficient of
determination was r2  0.952, and at 10-20 cm it was r2  0.845, suggesting that these
egments predicted TLV changes.
onclusion: Serial interval assessment of limb volume segments may be an important
linical tool to detect early-onset lymphedema before TLV changes.
PM R 2011;3:1098-1105
INTRODUCTION
Breast cancer–related lymphedema (BCRL) is defined as an abnormal accumulation of fluid
in the soft tissues of the upper limb [1]. Clinically apparent BCRL is a visible and often
palpable swelling. This condition is a uniquely progressive and chronic late effect of breast
cancer treatment that contributes to loss of limb function and disability [2-4]. Prospective
interval limb volume assessment for the signs and symptoms of BCRL is widely prescribed
[5-7]. This approach contributes to early diagnosis and may prevent BCRL [6,8,9].
An optimal monitoring strategy involves a preoperative clinical assessment followed by ongoing
prospective surveillance to measure limb volume and subjective reports of arm symptoms [6,8-11].
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preoperatively, before lymphatic disruption occurs; with prospec-
tive monitoring, the clinician can detect the earliest onset of limb
volume changes, which may be subclinical [6]. Several valid mea-
surement tools exist and can be methodologically standardized to
accurately assess limb volume [12-16].
Historically, total limb volume (TLV) change has been the
objective measure used to identify and quantify BCRL. How-
ever, limb swelling related to BCRL often does not occur uni-
formly throughout the extremity. Anatomical differences in
lymphatic pathways of the limb have been identified radio-
graphically [17,18] and demonstrate segmental variance in
drainage from the deeper subfascial limb compartment, from
the forearm, and from the hand [19-22]. The clinical translation
of this work leads us to hypothesize that the onset of limb
swelling might also follow a segmental distribution and that
perhaps TLV may not be sensitive enough in some instances to
detect the early onset of BCRL.
The purpose of this study is to examine the relevance of
segmental volume changes in the upper limb before the onset of
BCRL. We hypothesized that measuring limb volume at 10-cm
segments of the arm would detect early swelling and may be
predictive of the onset of BCRL. We also sought to determine
whether these segmental volume measures would identify
changes over time with early treatment intervention.
METHODS
A total of 196 women with early-stage breast cancer provided
informed consent in accordance with the Declaration of Hel-
sinki and were enrolled in an observational prospective morbid-
ity study approved by the Institutional Review Board of the
National Naval Medical Center. Patients were excluded from
enrollment if they had bilateral breast cancer or a history of
upper extremity or neck trauma or surgery, or if they were male.
Subjects were evaluated by a physical therapist for an initial
(baseline) examination and at 1, 3, 6, 9, and 12 months postop-
eratively. Bilateral upper extremity range of motion and strength
were tested with the subjects seated. Volume and girth measure-
ments for both upper limbs were obtained in a standard position
as described by Stout Gergich et al [6] with the use of an
optoelectronic volumeter containing a framed infrared scanning
system, the Perometer (Pero-System Messgerate; Am Tescher
Busch, Wuppertal, Germany). This instrument was designed
specifically to measure girth (cm) and volume (mL) of the upper
or lower extremities and has been validated for use in a clinical
environment [23]. Tests and measures were repeated at each
follow-up visit and any postural asymmetries, cording, swelling,
and/or seromas by visual inspection and palpation were re-
corded by the therapist. In addition, physical activity, pain, and
fatigue were subjectively reported by the patient.
A total of 46 of 196 women with early-stage breast cancer
were diagnosed with subclinical lymphedema (defined as3%
volume increase of the affected limb from the preoperative
measurement and with consideration for the contralateral limb[6]) at an average 6.9 months (standard deviation [SD] 4.3;
range, 1-18 months) after surgery. Segmental limb volume data
that had been captured by optoelectronic infrared perometry at
baseline and at interval follow-up visits before the onset of
lymphedema were available for 45 of the 46 women.
Interval arm volume measurements taken before the onset
of lymphedema at 10-cm segments along the length of the
limb were analyzed retrospectively. The 0 point was marked
at the wrist crease, and one segment was defined for each
10-cm increment along the limb. The hand was not included
in this analysis. This method yielded 4 limb segments with
the 0 point at the wrist: 0-10 cm, 10-20 cm, 20-30 cm, and
30-40 cm.
With the use of perometer software, circumferential girth
was obtained at these segmental markers at each interval mea-
surement before the onset of BCRL. Limb segment volume was
calculated on the basis of these circumferences with the use of a
truncated cone formula in Microsoft Access [24]. TLV was
derived in 2 ways: first, the aggregate sum of the volume of the
segments was calculated to yield TLV from 0 to 40 cm. Second,
80% of the length of the limb as measured from the ulnar styloid
process to the acromion process was obtained and perometer
software was used to calculate the TLV.
For the purposes of analysis, subjects were included in the
lymphedema group upon diagnosis of subclinical BCRL. We
used a case-control design, and an age-matched control
group of subjects from within the same prospective cohort
who had not been diagnosed with lymphedema was selected.
Therefore the control group highlights differences in patient
and tumor characteristics and in breast cancer treatment
between the groups.
All statistical analysis was performed with the use of SPSS
version 17 (Chicago, IL). Descriptive statistics were com-
puted for all variables, with significance set at an of P .05.
epeated-measures multivariate analysis of variance [25] was
used to compare segmental volumes (0-10, 10-20, 20-30,
and 30-40 cm) between the lymphedema and control groups
(group  between group comparison) at preoperative base-
line assessment, at the time of diagnosis of BCRL, and at the
time of follow-up after early intervention (time  within
comparison) for the affected limb and contralateral (unaf-
fected) limb. Assumptions for the multivariate analysis of
variance were met with a normal probability distribution and
nonsignificant tests of sphericity.
Linear regression analysis with the use of a least-squares
method was performed to determine the strength of the
relationship between TLV from 0-40 cm with segmental
volumes from 0-10 cm, 10-20 cm, 20-30 cm, and 30-40 cm
at the time of diagnosis of BCRL (Figures 1 and 2). The
residuals (ie, the deviations from the fitted line to the ob-
served values) were examined to determine the validity of the
model. We assessed the strength of the relationship by cal-
culating the coefficient of determination [26].
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The lymphedema group consisted of 45 women with early-
stage breast cancer with a mean age of 55.8 years (range,
34-82 years; SD 12.1). The control group comprised 45
women with a mean age of 55.8 years (range, 33-81 years;
SD  12.2). The physical characteristics of these groups are
hown in Table 1 and differed at baseline only with regard to
heir affected side from breast cancer (P  .029). Average
ody mass index (BMI) was not significantly different be-
ween groups at baseline; however, when BMI was categori-
ally analyzed (Table 1), BMI classification was significantly
ifferent for those classified as overweight (P .041). BMI was
ignificantly different between groups after early intervention for
CRL (P .043), suggesting that the lymphedema group expe-
ienced weight gain during the course of treatment for breast
Figure 1. Regression for affected upper limb segmental vol-
ume 10-20 mL at time of diagnosis of breast cancer–related
lymphedema of the control group (A) and the lymphedema
group (B).ancer. Table 2 shows the breast cancer treatment character-stics of the groups. The groups were significantly different
egarding their chemotherapy (taxol, adriamycin, cytoxan
TAC]) (33.3%; P  .004), procedure for breast reconstr-
ction (26.7%; P  .001), and occurrence of postoper-
tive axillary web syndrome (35.6%; P  .026), suggesting
hat these factors may have contributed to the onset of
ymphedema.
Statistically significant increases in TLV were noted in the
ymphedema group from baseline to the time of diagnosis.
ignificant increases at the 10-20 cm and 20-30 cm segments
ere noted before the diagnosis of subclinical lymphedema,
t diagnosis, and after early intervention compared with the
ontralateral limb. Table 3 outlines segmental and TLV
hanges over time for the lymphedema group, noting lower
nd upper bound confidence intervals.
Linear regression analysis at time of diagnosis of
ymphedema for TLV and segment 10-20 cm yielded a coef-
Figure 2. Regression for affected upper limb segmental volume
20-30 mL at time of diagnosis of breast cancer–related
lymphedema of control group (A) and lymphedema group (B).
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1101PM&R Vol. 3, Iss. 12, 2011ficient of determination of r2  0.845 (Figure 1B) for TLV,
and segment 20-30 cm yielded a coefficient of determination
of r2 0.952 (Figure 2B), suggesting that segmental volume
changes at the 10-20 cm and 20-30 cm segments may explain
the change in TLV.
DISCUSSION
The concept of segmental drainage is historically referred to in
lymphatic anatomy, and these patterns of segmental drainage have
been implicated in the development of lymphedema [27]. This
concept is further supported by the recent work of Reynolds et al
[28], Uren et al [29], and Suami et al [30], whose segmental
ymphatic drainage evidence has propelled the concept of sentinel
ymph node biopsy in melanoma of the extremities.
Stanton et al [31] highlighted the segmental lymphatic drainage
athways of the upper extremity in BCRL. They demonstrate, with
ymphoscintigraphy, that lymphatic drainage pathways of the limb
o not flow in an absolute linear, progressive fashion and that
egmental variations do indeed exist [20]. These authors note seg-
ental drainage variations in the deeper subfascial compartments
f the upper limb, most notably in the muscle compartments and
Table 1. Baseline patient characteristics
Characteristic Group/Classificatio
Age Control
Lymphedema
Baseline weight, kg Control
Lymphedema
Weight at intervention Control
Lymphedema
Weight at follow-up Control
Lymphedema
Height, m Control
Lymphedema
BMI at baseline Control
Lymphedema
BMI at follow-up Control
Lymphedema
Control
n %
ffected limb
Right 27 6
Left 18 4
Dominant limb
Right 38 8
Left 7 1
BMI classification
25 (normal) 23 5
25-29.9 (overweight) 17 3
30 (obese) 5 1
ANOVA  analysis of variance; BMI  body mass index.
*P  .05 is significant with all interval data tested by univariate ANOVA at b
(baseline, onset of intervention, and follow-up).
†P  .05 is significant with nominal data tested by 2 test.he hand [21,32-34]. Our results demonstrate the clinical presen- fation of disrupted segmental pathways after breast cancer–mitigat-
ng therapies.
Stanton et al [20] noted an increase in the lymphatic
ressure in the muscle compartments of the upper limb
efore the onset of lymphedema. They theorize that pres-
ure may be increased in the deep compartments because
f the low compliance of muscle tissue. This increase in
ressure results in decreased lymph drainage from the
uperficial tissues into deeper tissues, which is a necessary
echanism in assisting the removal of fluid from the
ubcutaneous tissue. The epifascial lymphatics then be-
ome overloaded and are rendered inefficient in their
ptake and drainage of fluid. This scenario gives rise to the
heory that an initial clinical presentation of lymph con-
estion will be distributed in a segmental fashion local to
he muscle compartments [18,31,34]. Our clinical find-
ngs support this notion and suggest that changes at the
arliest onset of BCRL would likely occur in the superficial
issue in close proximity to the muscle, primarily the
orearm and distal upper arm, as we found.
The segments 10-20 cm and 20-30 cm include the proximal
Mean ( SD) P Value*
55.8 ( 12.2) .972
55.8 ( 12.1)
69.1 ( 15.3) .243
72.8 ( 14.8)
69.5 ( 15.1) .195
73.6 ( 14.9)
69.5 ( 15.2) .134
74.3 ( 14.7)
1.65 ( 0.07) .135
1.62 ( 0.06)
25.6 ( 5.9) .092
27.5 ( 5.1)
25.7 ( 5.9) .043*
28.1 ( 5.2)
Lymphedema
n %
17 37.8
28 62.2 .029†
40 89
5 11
15 33
16 36 .041†
14 31
between groups. Weight and BMI were tested by repeated-measures ANOVAn
0
0
4
6
1
8
1
aselineorearm and the mid to distal upper arm, commonly referred to
S
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muscle tissue bulk that includes the deep forearm compartment.
Mellor et al [21] found that in these regions of the arm, fluores-
cent tracer was transported over a greater epifascial distance of
the forearm before draining deep in the swollen arm of women
with BCRL. These investigators suggest that microlymphatic
changes occur in the swollen arm, namely a local superficial
rerouting of lymph drainage in the forearm. Because of this
dispersion of fluid through the superficial tissues, we suggest
that optimal measurement for lymphedema should be compre-
hensive; however, segments 10-20 cm and 20-30 cm may have
the most clinical utility because they are highly significant in
their ability to explain a large amount of the variance in TLV and
should be explicitly targeted and monitored for meaningful
change.
When BCRL is diagnosed and managed at its earliest stages,
Table 2. Breast cancer treatment characteristics
Subject Characteristics Classification
Type of BC DCIS
IDC
DCIS  IDC
Other
Stage of BC 0
I
II
III
Surgery MRM
BCT
Breast reconstruction No
Muscle flap
Implant
Lymph node dissection None
ALND
SLNB
Radiation therapy Yes
Hormone therapy No
SERMs
AIs
Chemotherapy No
AC
TAC
Other
eroma Yes
xillary web Syndrome Yes
Control
Median Mean %  SD M
No. nodes sampled 8 10.4 9.8
No. nodes positive 0 1.2 4.3
BC  breast cancer; DCIS  ductal carcinoma in situ; IDC  invasive ducta
CT  breast-conserving therapy; ALND  axillary lymph node dissection; S
AI  aromatase inhibitor; AC  Adriamycin/cytoxan; TAC  taxol, Adriamy
*P  .05 is significant with all interval data tested by univariate ANOVA at b
(baseline, onset of intervention, and follow-up).
†P  .05 is significant with nominal data tested by 2 test.the condition can be controlled and the adverse effects mini-mized [35]. Early detection of lymphedema relies on a prospec-
tive surveillance model and sensitive measurement techniques
for accurate assessment and management [35]. The effectiveness
of any measurement device to quantify BCRL is constrained by
the methodology with which it is used. Preoperative volume
measurement enables quantification of normal interlimb vari-
ance [36]. Only by assessing our subjects’ “normal” preoperative
limb differential were we able to use serial postoperative mea-
surements to effectively assess these segmental changes over
time and eventually detect subclinical BCRL. Bilateral limb vol-
ume assessment should be conducted because weight changes
and postsurgical swelling can affect both limbs [37]. Weight
changes and postsurgical swelling may account for the volume
change we observed in our lymphedema group at the 30-40 cm
segment on the unaffected limb over time (Table 3).
We used optoelectronic perometry for serial volume mea-
Control
45), n (%)
Lymphedema
(n  45), n (%) P Value
8 (17) 6 (13) .171
27 (61) 19 (43)
7 (16) 15 (33)
3 (6) 5 (11)
8 (17) 3 (6) .087
18 (40) 12 (27)
14 (32) 25 (56)
5 (11) 5 (11)
25 (56) 20 (44) .459
20 (44) 25 (56)
29 (64) 33 (73) .001*
0 (0) 7 (16)
16 (36) 5 (11)
6 (14) 5 (11) .110
28 (62) 35 (78)
11 (24) 5 (11)
30 (66) 35 (78) .173
11 (24) 12 (27) .969
25 (56) 24 (53)
9 (20) 9 (20)
25 (56) 14 (32) .004*
17 (38) 15 (33)
2 (4) 15 (33)
1 (2) 1 (2)
4 (9) 9 (20) .115
7 (16) 16 (36) .026*
Lymphedema
ax Median Mean %  SD Min-Max P Value†
14 13.2 10.0 0-48 .183
0 2.2 5.8 0-37 .345
oma; ANOVA  analysis of variance; MRM  modified radical mastectomy;
sentinel lymph node biopsy; SERM  selective estrogen receptor modulator;
xan; SD  standard deviation; min-max  minimum-maximum.
between groups. Weight and BMI were tested by repeated-measures ANOVA(n 
in-M
0-37
0-28
l carcin
LNB 
cin, cyto
aselinesurement. Perometry uses infrared light to capture limb con-
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1103PM&R Vol. 3, Iss. 12, 2011tour, and the associated software program calculates TLV and
offers interlimb comparison. The perometer, although highly
sensitive to limb volume change [23], cannot be used to gauge
specific tissue-related changes in the limb. Other measurement
tools can reliably measure segmental limb volume, including
circumferential measurement and multifrequency bioelectrical
impedance [14,38], and when it is used in the context of a
rospective model of care, it will enable the earliest diagnosis of
ymphedema, which may be subclinical in nature.
Swelling may occur at any point during and after breast
ancer treatment. Postoperative acute swelling affects both
imbs in the short-term period after surgery, which empha-
izes the need for bilateral limb monitoring [37]. The average
time to onset of BCRL in our cohort was 6.9 months, suggest-
ing that monitoring during the first year will enable early
detection and treatment. Notable changes in deep tissue
lymph pressure have been prospectively assessed and are
reported to begin at 7 months postoperatively and progress
beyond 24 months [20]. This finding contributes to the
concept that early subclinical changes possibly occur in the
deep compartments and suggests that such segmental
changes may provide the earliest presentation of volume
change before the onset of BCRL and may require ongoing
assessment for a concomitant period. Recent prospective
work by Bar Ad et al [39] supports the progressive nature of
CRL, suggesting that patients with mild lymphedema are at
n increased risk for progression. Although our analysis only
onsidered the first postoperative year, the importance of
ontinued monitoring beyond the first year after treatment
Table 3. Interlimb volume differences and their change over
Limb Segment Volume
Control
Interlimb Volume
Difference, mL
aseline
0-10 mean (SD) 7.4 ( 47.7)
10-20 4.0 ( 69.3)
20-30 2.7 ( 99.6)
30-40 0.3 ( 128.3)
Total limb 80% arm length 6.7 ( 278.5)
Intervention
0-10 2.4 ( 45.8)
10-20 (P  .044)* 4.7 ( 72.3)
20-30 (P  .001)* 0.4 ( 105.0)
30-40 1.5 ( 140.8)
Total limb 80% arm length 3.5 ( 283.6)
Follow-up
0-10 1.4 ( 45.4)
10-20 2.5 ( 69.8)
20-30 (P  .04)* 5.7 ( 106.2)
30-40 12.7 ( 139.3)
Total limb 80% arm length 9 ( 282.5)
MANOVA  multivariate analysis of variance.
*P  .05 is significant for change over time as calculated by MANOVA.
†P  .05 is significant for change between groups as calculated by MANOhould be considered.Interestingly, the breast cancer treatment characteris-
tics of our lymphedema group demonstrated significant
differences from the control group that were unexpected.
Patients in the lymphedema group had more breast recon-
struction procedures, tended to have taxane-based chemo-
therapy regimens, and had higher rates of axillary web
syndrome after surgery. This relatively small cohort high-
lights variables that may be associated with BCRL. The
authors of a previous study have demonstrated a possible
association but failed to identify the significance of che-
motherapy as a definitive risk factor associated with the
development of BCRL [40]. Future research should iden-
tify and study these variables in larger cohorts to deter-
mine whether they are indeed risk factors in the develop-
ment of early BCRL.
Our work suggests that pericubital upper limb segment
volume changes are highly predictive of changes in TLV. The
sensitivity and specificity of using only limb volume change
to diagnose lymphedema has yet to be analyzed; therefore, a
comprehensive evaluation of the patients’ reported symp-
toms, risk factors, and clinical presentation all should be
considered in the context of a prospective surveillance model
[11,15]. This approach may optimize the early diagnosis of
lymphedema, perhaps in a subclinical stage.
CLINICAL IMPLICATIONS
A prospective surveillance approach to identifying lymphedema
is an effective method to detect and treat the condition at its
mphedema
rlimb Volume
ifference, mL
95% Confidence Interval,
Lymphedema Group
Lower Bound Upper Bound
58.8) 281.2 319.0
96.5) 417.0 478.1
152.0) 545.2 637.3
206.0) 632.7 754.4
403.3) 1238.7 1483.4
61.9) 297.7 339.2
99.7) (P  .001)† 439.5 503.6
149.0) (P  .001)† 582.4 637.6
209.9) 680.8 810.0
416.6) 1249.0 1496.5
59.1) 290.6 328.5
96.5) 429.1 488.4
142.6) (P  .001)† 570.6 657.6
184.4) 673.8 786.5
389.6) 1260.1 1495.4time
Ly
Inte
D
1.4 (
5.2 (
4.0 (
1.6 (
9.3 (
17.7 (
28.4 (
30.9 (
3.6 (
81.4 (
8.6 (
9.5 (
19.1 (
12.4 (
36.3 (earliest onset [6,8,9]. The pericubital segments of the limb show
1104 Stout et al SEGMENTAL LIMB VOLUME CHANGES BEFORE LYMPHEDEMAa significant increase in volume compared with the other limb
segments before the onset of subclinical lymphedema. Many
measurement tools provide excellent clinical utility for the
quantification of limb volume. Only when preoperative assess-
ment of limb volume followed by a prospective interval surveil-
lance model of care is implemented will practicing clinicians be
adept in early detection of BCRL. This work suggests that the
10-20 cm and 20-30 cm pericubital regions of the limb demon-
strate change in volume that is predictive of TLV change, asso-
ciated with subclinical BCRL. A clinical approach that is simple
and targeted to these segments may successfully detect early
BCRL when serial measurements are taken in the context of a
comprehensive prospective model of care. We suggest that a
comprehensive prospective surveillance model of care is opti-
mal for early detection of BCRL.
LIMITATIONS
This study demonstrates meaningful volumetric data that are
shown to be important in detecting early TLV changes. How-
ever, this study is a relatively small subset analysis based on a
larger cohort trial. Although the trial was prospective in nature,
the analysis of limb volume was performed retrospectively and
focused on a known diagnosis of lymphedema. Ideally, a pro-
spective trial in which serial segmental measures are conducted
with prospective management of meaningful volume changes,
preferably with randomization, ultimately will determine the
validity of these data for diagnostic purposes.
We focused only on volume changes experienced before
the onset of lymphedema. This study contributes only one
factor to the overall clinical assessment of a patient. Assess-
ment and diagnosis of early-stage lymphedema requires a
comprehensive approach that includes patient-reported
symptoms and risk factor assessment [11,40-42].
Our assessment of limb volume excluded the hand. The
perometer methodology previously described does not in-
clude a measure of the hand. Specific drainage pathways are
noted to be dedicated to the hand [17], which further con-
tributes to the premise of segmental lymphatic drainage.
These measures were not captured or quantified in our
cohort; therefore, it is not known whether hand volume
changes would affect these findings.
IMPLICATIONS FOR FUTURE RESEARCH
Future research would benefit from studying methodology for
segmental measurement in the context of a prospective clinical
assessment model. Strong predictive factors have been identified in
relation to BCRL. In addition, cancer treatment–related risk factors
associated with the onset of BCRL are widely reported. A model for
risk stratification and clinical prediction rules could be evaluated
and extrapolated from these data.
Novel compression therapy trials should consider investigating
the implicationsofcompressionapplicationat thesegmentsmostatrisk. Compression gradients that offer greater stiffness in the gar-
ment over these tenuous areas should be fabricated and studied in
the context of early intervention.
These findings may have implications for early diagnosis
of lower extremity lymphedema. Directions in future re-
search could aim to identify a threshold for volume change
consistent with lymphedema and assess associated segmental
changes in the lower extremity.
CONCLUSION
Before the onset of BCRL, upper limb segmental limb volume
changes occur that are predictive of TLV changes. Segmental
assessment of the limb in the absence of swelling may be an
important clinical tool to detect early-onset lymphedema. An
optimal clinical approach includes prospective surveillance
to monitor changes in limb volume that may be predictive of
the onset of lymphedema.
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